Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Azienda Ospedaliero Universitaria Maggiore della Carita | OTHER |
| Azienda USL Reggio Emilia - IRCCS | OTHER_GOV |
| Institute of Pathology, Locarno, Ticino, Switzerland | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
The study aims at developping and validating an integrated clinico-molecular model for an accurate identification of FL patients who are progression free and progressed, respectively, at 24 months after treatment.
Already existing and coded tumor biological material and health-related personal data will be retrospectively collected. FL diagnosis will be confirmed by central pathology review. Tumor somatic mutations, immunoglobulin gene rearrangement and mutation status will be analyzed by targeted deep next generation sequencing of tumor genomic DNA. Gene expression profiling will be performed by targeted RNA-Seq of biopsy-derived RNA.
An immunohistochemistry panel assessing both tumor phenotype and microenvironment cellular composition will be assessed by Tissue macroarray. FISH will be performed to characterize the most recurrent follicular lymphoma chromosomal translocations.
The adjusted association between exposure variables and progression free survival will be estimated by Cox regression. This approach will provide the covariates independently associated with progression free survival that will be utilized in the development of a hierarchical molecular model to predict progression free survival at 24 months. The hierarchical order of relevance in predicting 24 months progression free survival among covariates will be established by recursive partitioning analysis. Overall, this approach will allow the development of a multilayer dynamic model for anticipating progression within 24 months from treatment.
The model developed in the training set will be tested in the validation sets and the model performance (c-index and net reclassification improvement) in the validation set will be compared with that in the training set. The accuracy of the multilayer model in predicting progression free survival at 24 months will be compared against the FLIPI using c-index and net reclassification improvement.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Training cohort | Cohort of follicular lymphoma patients for the development of the multilayer risk stratification model | ||
| Validation cohort | Cohort of follicular lymphoma patients for the validation of the developed multilayer risk stratification model |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Accuracy of multilayer personalized stratification model | Assessment of multilayer personalized stratification model accuracy in the identification of patients who are progression free at 24 months after first line therapy plus the proportion of patients correctly identified as progressed within 24 months after first line therapy | 24 months after first line treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Progression free survival | Time elapsed from treatment start to progression (event), death (event) or last follow-up (censoring) | From treatment start to progression / death / last follow-up, up to 13 years of follow-up |
| Overall survival |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Follicular lymphoma patients
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Davide Rossi, MD, PhD | Oncology Institute of Southern Switzerland | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Arcispedale Santa Maria Nuova, AUSL IRCSS, Hematology Department | Reggio Emilia | RE | 42123 | Italy | ||
| Azienda Ospedaliera Universitaria Maggiore della Carità |
Not provided
| ID | Term |
|---|---|
| D008224 | Lymphoma, Follicular |
| ID | Term |
|---|---|
| D008228 | Lymphoma, Non-Hodgkin |
| D008223 | Lymphoma |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
FFPE tissue specimen
Time elapsed from treatment start to death (event) or last follow-up (censoring)
| From treatment start to death / last follow-up, up to 13 years of follow-up |
| Time to transformation | Time elapsed between treatment start and transformation (event), progression without transformation (censoring), death (censoring) or last follow-up (censoring) | From treatment start to transformation or progression without transformation or death or last follow-up, up to 13 years of follow-up |
| Novara |
| 28100 |
| Italy |
| Institute of Oncology Research | Bellinzona | Canton Ticino | 6500 | Switzerland |
| Institute of Pathology | Locarno | Canton Ticino | Switzerland |
| D008232 |
| Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |